Highlights
- Divarasib demonstrates significantly improved progression-free and overall survival compared to first-generation KRAS G12C inhibitors sotorasib and adagrasib in previously treated advanced NSCLC.
- Real-world evidence confirms clinical efficacy and tolerability of sotorasib but highlights challenges related to dosing and patient frailty.
- Matching-adjusted indirect comparisons indicate comparable efficacy between sotorasib and adagrasib, with sotorasib exhibiting a more favorable safety profile, especially in patients with brain metastases.
- Circulating tumor DNA (ctDNA) dynamics serve as predictive biomarkers for treatment response and resistance across therapies, underscoring the importance of molecular monitoring.
Background
Specialty calculators
For clinical reference; use professional judgment.
